Impact of the use of Flebon in the treatment of patients with Lipedema

Impact of the use of Pycnogenol in the treatment of patients with Lipedema

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-6bcnbpq

Enrollment

Unknown

Registered

2025-01-10

Start date

2024-02-23

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipedema

Interventions

This is a two-arm, triple-blind, randomized controlled clinical study containing 100 participants who meet the eligibility criteria. These patients will be probabilistically allocated to one or anothe

C17.300.451

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women between 18-40 yeras old;with lipedema

Exclusion criteria

Exclusion criteria: Pregnant women;patients usig anorexigens;patients using anabolic medicines;patients on restrictive diets;patients with a proven adverse reaction to Pycnogenol

Design outcomes

Primary

Measure	Time frame
It is expected to find a progressive improvement in the quality of life questionnaire for Lipedema after the start of the study;It is expected to find a reduction in the disposition of total body fat, and mainly in the lower limbs, through bioimpedance performed at the beginning of the study, 4 and 8 weeks after	—

Secondary

Measure	Time frame
It is expected to find a decrease in the thickness of the subcutaneous tissue through ultrasound performed at the beginning of the study and 8 weeks later	—

Countries

Brazil

Contacts

Public ContactBrenno Augusto Mello Netto

B2 Medicos Associados

contato@brennoseabra.com+55 (27) 992233757

Outcome results

None listed

Source: REBEC (via WHO ICTRP)